by Marisa Wexler, MS | Nov 17, 2025 | Myeloma News
The U.S. Food and Drug Administration (FDA) has approved ziftomenib to treat adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 gene mutation who have no satisfactory alternative treatment options. The once-daily oral therapy,...
by Marisa Wexler, MS | Nov 14, 2025 | Myeloma News
Capsovision is requesting that the U.S. Food and Drug Administration (FDA) expedite the development of its CapsoCam UGI capsule endoscopy system as a potential tool for detecting early-stage pancreatic cancer. The CapsoCam system is similar to a large pill containing...
by Margarida Maia, PhD | Nov 13, 2025 | Myeloma News
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to tinostamustine, a treatment candidate from Purdue Pharma that aims to extend survival for people with malignant gliomas, the developer announced. Gliomas are a group of tumors that form...
by Marisa Wexler, MS | Nov 12, 2025 | Myeloma News
A combination of chemotherapy and immune-modulating therapies administered directly into the abdomen may help control ovarian cancer that has spread within the abdominal cavity, data from a small clinical trial show. Results from the study were discussed earlier this...
by Margarida Maia, PhD | Nov 12, 2025 | Myeloma News
The U.S. Food and Drug Administration (FDA) has approved Darzalex Faspro (daratumumab and hyaluronidase) for adults with high-risk smoldering multiple myeloma, making it the first and only approved treatment for this slow-growing type of multiple myeloma. People with...
by Steve Bryson, PhD | Nov 10, 2025 | Myeloma News
One-time treatment with vispa-cel (CB-010), Caribou Biosciences’ off-the-shelf CAR T-cell therapy candidate, resulted in durable responses in people with hard-to-treat large B-cell lymphoma (LBCL). That’s according to data from the ongoing Phase 1 ANTLER clinical...
